learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Androgenetic Alopecia: Combing the Hair Follicle Signaling Pathways for New Therapeutic Targets and More Effective Treatment Options
New treatments for hair loss may target specific pathways and generate new hair follicles.
research New Intranasal and Injectable Gene Therapy for Healthy Life Extension
Gene therapy in mice increased lifespan and improved health without causing cancer.
research Advanced Polymer Hydrogels That Promote Diabetic Ulcer Healing: Mechanisms, Classifications, and Medical Applications
Special gels help heal diabetic foot sores and reduce the risk of amputation or death.
research Combination of an Engineered Lactococcus Lactis Expressing CXCL12 with Light-Emitting Diode Yellow Light as a Treatment for Scalded Skin in Mice
The combined treatment with engineered bacteria and yellow LED light improved wound healing in mice.
research Safety Aspects of Androgen Treatment with 5α-Dihydrotestosterone
DHT is a strong androgen that may pose less risk to the prostate compared to testosterone.
Community Join
5 / 73 resultscommunity Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days!
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community Amplifica AMP-303 study results are expected late this summer
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.